Humira Biosimilar Drumbeats: Biocon Claims Edge For Adalimumab In US

Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.

Biocon Well Placed To Debut Humira Biosimilar In The US • Source: Shutterstock

Biocon, Ltd. says it is well-placed to debut its partnered biosimilar to AbbVie Inc.’s Humira (adalimumab) in the US next year.

Matthew Erick, chief commercial officer, advanced markets, Biocon Biologics Ltd (BBL), indicated that while no biosimilar manufacturer has “everything to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip